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Abstract
Background: Traumatic brain injury (TBI) is the leading cause of long-term disability in working age adults. Recent
studies show that most acute TBI patients demonstrate vestibular features of dizziness and imbalance, often from
combined peripheral and central vestibular dysfunction. Effective treatment for vestibular impairments post-TBI is
important given its significant adverse impact upon quality of life and employment prospects. The most frequent
peripheral vestibular disorder in acute TBI is benign paroxysmal positional vertigo (BPPV), affecting approximately
half of acute cases. Although there is effective treatment for idiopathic BPPV, there are no high-quality clinical data
for post-TBI BPPV regarding its prevalence, natural history, which treatment is most effective and when is the best
time to treat. In particular, observational studies suggest post-TBI BPPV may be recurrent, indicating that hyperacute
treatment of BPPV may be futile. Given the potential hurdles and the lack of accurate post-TBI BPPV data, the
current study was designed to provide information regarding the feasibility and optimal design of future large-scale
prospective treatment studies that would compare different interventions and their timing for post-TBI BPPV.
Method: A multi-centre randomised mixed methods feasibility study design was employed. We aim to recruit
approximately 75 acute TBI patients across a range of clinical severities, from three major trauma centres in London.
Patients will be randomised to one of three treatment arms: (1) therapist-led manoeuvres, (2) patient-led exercises
and (3) advice. Participants will be re-assessed by blinded outcome assessors at 4 and 12 weeks. Acceptability of the
intervention will be obtained by patient interviews at the end of their treatment and therapist interviews at the end
of the study. Primary outcomes relate to feasibility parameters including recruitment and retention rates, adverse
events and intervention fidelity. We will also aim to provide a more accurate estimate of the prevalence of BPPV in
TBI cases on the trauma ward.
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Discussion: The multi-centre nature of our feasibility study will inform the design of a future prospective treatment
trial of BPPV in acute TBI. Important parameters we will obtain from this study, key for designing a future
prospective treatment study, include estimating the prevalence of BPPV in TBI patients admitted to UK major
trauma wards, and elucidating both patient and care-provider barriers in delivering BPPV treatment.
Trial registration: ISRCTN, ISRCTN91943864. Registered on 10 February 2020.
Keywords: Feasibility study, Traumatic brain injury, Benign paroxysmal positional vertigo, Rehabilitation
Background
Traumatic brain injury (TBI) is the most common cause
of long-term disability in working age adults [1]. Indeed,
in England and Wales, it is estimated TBI results in 1.4
million emergency visits per year [2], costing the econ-
omy £15 billion [3] and resulting in a significant impact
on health-related quality of life for patients and carers
[4]. Amongst the plethora of impairments experienced
by TBI survivors, vestibular features or complaints of
dizziness and/or imbalance are common, with large
numbers of patients remaining symptomatic at 5-year
follow-up [5].
The impact of dizziness on TBI survivors can be varied
and burdensome, affecting physical, psychological and
socioeconomic domains [6]. Acute and long-lasting diz-
ziness can directly affect physical health, with implicit
links to imbalance and therefore risk of falls [7, 8], which
affect half of community-dwelling TBI survivors [9, 10].
The well-documented impact of falls on physical and
psychological morbidity, mortality [11] and healthcare
resource consumption [12] necessitates risk factors such
as dizziness be appropriately managed. Imbalance and
dizziness can also impair mental wellbeing, as demon-
strated by studies describing direct links between the ves-
tibular system and brain areas involved in emotional and
cognitive processing [13–15]. Further, Chamelian et al.
(2004) demonstrated dizziness to be an independent pre-
dictor of return to work, reporting only a third of dizzy
patients had returned to work at 6 months compared to
three quarters of patients without dizziness [16]. The im-
plications of long-term unemployment not only include a
socioeconomic burden for patients and their families, but
also involve a wider impact on work productivity and
costs for employers and society. Indeed, findings from a
large observational study demonstrated the majority of pa-
tients with dizziness had reduced their workload and lost
working days at just 3months post onset of symptoms
[17]. Therefore, the complex interplay between dizziness,
physical health, neuropsychiatric function and socioeco-
nomic factors provides the rationale for enhancing early
diagnosis and treatment of dizziness.
The most frequently diagnosed cause of dizziness fol-
lowing TBI is benign paroxysmal positional vertigo
(BPPV), theorised to be due to mechanical displacement
of calcium carbonate ‘crystals’ or otoconia (Fig. 1) during
the head injury itself [18]. As a result, patients typically,
but not always, experience a sense of illusory self-
motion when moving their head. Importantly, idiopathic
BPPV is also associated with imbalance and falls [19]
and hence, BPPV could exacerbate imbalance due to
brain injury. Surprisingly, there is little evidence explor-
ing falls in acute post-traumatic BPPV. Previous research
in sub-acute TBI demonstrates the prevalence of post
traumatic BPPV to range from 11 to 28% [20–22]; how-
ever, pilot data collected in acute TBI patients at St Mary’s
Hospital, London, suggests it may be as high as 55% [23].
Further work is indicated to establish more accurate
prevalence data. In particular, post-traumatic BPPV is
thought to be more complex than the idiopathic form,
with higher rates of multi-canal diagnoses and more treat-
ment sessions required for resolution [21]. However, con-
flicting data exists regarding recurrence rates [21, 24].
Robust clinical guidelines [25] direct the treatment of
idiopathic BPPV, involving repositioning manoeuvres or
repeated movements of the head and body to relocate the
otoconia within the inner ear canals. However, there is a
relative paucity of research regarding treatment of post
traumatic BPPV, in particular regarding factors such as
optimum dosage, or the most beneficial time to treat. The
few studies which have examined treatment effectiveness
were solely completed in sub-acute or chronic TBI pa-
tients and are further limited by their retrospective nature
[21, 24], small sample size [20, 21] and lack of focus on
BPPV resolution, symptom burden, or other patient-
centred outcomes. The scarcity of acute prospective data
noted may be a factor in the variability noted in routine
assessment and treatment of post traumatic BPPV.
Indeed, despite the relatively high prevalence of post
traumatic BPPV, emerging evidence suggests patients
are not routinely assessed during the acute stages of
their injury [26]. Our pilot work corroborates such data,
indicating variable assessment and treatment of post
traumatic BPPV appears to be complicated by two fac-
tors: (1) vestibular agnosia—impaired dizziness sensa-
tion which is also linked to imbalance via damage to the
right temporal lobe circuits [27], and (2) clinician factors
including insufficient training or skills. Vestibular agnosia
may lead to a reduction in patients’ ability to report
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dizziness. This is clinically meaningful as patients with
treatable diagnoses such as BPPV will not be assessed or
treated if screening is solely based on symptoms. An initial
report by Calzolari et al. [27] demonstrated vestibular agno-
sia leads to a seven fold reduction in clinician recognition
of BPPV [27]. Furthermore, early results from a qualitative
study exploring barriers to vestibular assessment and treat-
ment at a major trauma centre in London demonstrated a
variety of role and knowledge-based factors were linked
with a lack of routine assessment and treatment of dizzi-
ness [28]. This is perhaps unsurprising given national head
injury guidelines contain no reference to ‘vestibular’ or ‘diz-
ziness’ assessments following head injury [2]. Therefore, the
presence of vestibular agnosia and the lack of routine ves-
tibular assessment and treatment may heighten the risk of
clinically significant conditions such as post traumatic
BPPV remaining undiagnosed, with patients predisposed to
the acute and long-lasting sequelae of dizziness.
In summary, BPPV seems to affect the majority of
acute TBI patients with possible long-lasting physical,
psychosocial and economic consequences. Despite this,
for a variety of reasons acute assessment and treatment
is sub-optimal, whilst insufficient data exists to support
decisions regarding effective treatment.
Aim and objectives
The primary aim of this study is to evaluate the feasibil-
ity of conducting a future randomised controlled trial
(RCT) investigating the effectiveness of treating BPPV in
acute TBI.
Primary objectives focus on feasibility outcomes and
will aid the design of a future definitive trial:
– To establish trial recruitment rates, including the
willingness of patients to be randomised to a
treatment arm
– To determine trial retention rates, the fidelity of the
intervention, its acceptability to participants and
clinicians and any missing data
– To explore the incidence of adverse events
Secondary objectives will also support the design of a
future RCT. They include:
– An estimate of the prevalence of BPPV in acute TBI
– Calculating effect sizes for primary and secondary
outcome measures to thereby inform sample size
estimates for future studies
– Examining the relationship between vestibular




Currently, it is not routine practice in all major trauma
centres to assess for or treat BPPV in acute TBI. In order
Fig. 1 Schematic representation of displaced otoconia within the posterior semi-circular canal. Figure kindly provided by John Corcoran,
April 2020
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to implement any long-term changes to screening and/
or treatment behaviours, it is necessary to identify any
possible barriers to such changes in clinical practice.
Therefore, a feasibility study utilising both quantitative
and qualitative methods was deemed appropriate.
This multi-centre, mixed methods randomised feasibil-
ity trial will comprise a randomised trial with two inter-
vention arms and one comparator arm, and a
subsequent qualitative study (Fig. 2). Reporting of this
protocol will comply with the SPIRIT statement.
– Phase 1 will consist of a feasibility trial involving
approximately 75 patients randomised to one of the
three arms.
– Phase 2 will qualitatively explore the experiences of
patients and clinicians participating in the trial and
their views regarding progression to a randomised
controlled trial. Patients who decline to take part
will be invited for their feedback to enhance
recruitment for a future trial.
Phase 1—feasibility trial
Recruitment
Trauma care in England is delivered through specialist
centres [29]. Indeed, patients will be recruited from
major trauma centres in London. Direct members of the
care team will screen patients using inclusion and exclu-
sion criteria and provide eligible patients with an infor-
mation sheet and consent form.
Eligibility criteria
Inclusion criteria consists of patients over the age of 18
with a non-penetrating head injury, able to provide in-
formed consent (or with a consultee willing to provide
advice), inpatient on a trauma or outlying ward and a
sufficient grasp of English to complete outcome
Fig. 2 SPIRIT figure
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measures. Patients will be excluded if they have a
current history of substance abuse, are medically un-
stable, are pregnant, have vascular or orthopaedic injur-
ies precluding neck extension, have active psychiatric
disease or a history of psychotic disease, have a Glasgow
Coma Score less than 14, or have a current prescription
of phenytoin.
Assessment
Eligible patients who consent to take part in the study
will be assessed by a ward therapist for BPPV using a
Dix Hallpike manoeuvre (Fig. 3), which is the gold
standard diagnostic test [25]. Therapists (occupational
therapists and physiotherapists) will be trained to under-
take such manoeuvres prior to the study commencing.
Randomisation
Those diagnosed with BPPV will be randomised to one
of three intervention arms (Fig. 4). Patients testing nega-
tive for BPPV will not take further part in the trial. Ran-
domisation will occur through an online randomisation
platform (Sealed Envelope) which uses sequential treat-
ment assignment. Minimisation criteria will be used to
ensure groups are balanced. Trial participants and out-
come assessors will be blinded to group allocation; how-
ever, due to the physical nature of the interventions,
blinding of the therapists delivering the intervention will
not be possible.
Interventions
Participants will be randomly allocated to one of three
arms: (1) therapist-led repositioning manoeuvres, (2)
patient-led exercises, or (3) advice.
1. Therapist-led repositioning manoeuvres
Repositioning manoeuvres are physical movements of
the head and body typically used to treat idiopathic or
traumatic BPPV [25]. Ward therapists will be taught to
perform repositioning manoeuvres as per clinical guide-
lines [25]. Those diagnosed with BPPV affecting both left
and right sides will be treated with the most symptom-
atic side first (or the side with the most intense nystag-
mus if the participant is not symptomatic). A repeat
diagnostic test will be subsequently performed to deter-
mine the success of the intervention. The number of
manoeuvres required for resolution of BPPV will vary
between participants. If acceptable, the therapist will
continue completing manoeuvres, up to a maximum of
three manoeuvres per session, and a maximum of three
sessions (over subsequent days where applicable). Par-
ticipant discomfort, nausea, or vomiting would be indi-
cations to cease treatment. Any adverse events or
reasons to stop the intervention will be recorded.
2. Patient-led exercises
Patient-led or Brandt-Daroff exercises are a form of
physical self-treatment involving repeated movements of
the head and trunk prescribed by clinicians as an alter-
native to, or in tandem with, repositioning manoeuvres.
The National Institute of Clinical Evidence suggest
Brandt-Daroff exercises as a treatment option for idio-
pathic BPPV [30], although their effectiveness is un-
known post TBI.
Ward therapists will teach participants and carers
(where required) the Brandt-Daroff exercises. A repeat
diagnostic test will be completed. Following treatment,
participants will be instructed to complete the exercises
twice per day for 2 weeks, using a standardised, written
exercise sheet. Participants will be asked to complete a
home diary to record their adherence with the exercises.
Fig. 3 Schematic representation of the Dix Hallpike, the diagnostic test for BPPV. Patients lie supine with their head rotated 45° and extended 20°.
Figure kindly provided by John Corcoran, April 2020
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3. Advice
Ward therapists will provide participants with verbal
and written advice. This will comprise ensuring adequate
fluid intake, taking precautions when mobilising inde-
pendently on the ward or at home and trying to ensure
normal head and body movement patterns. Advice will
be provided in the course of the participant’s hospital
stay, during a scheduled therapy session. Such advice is
based on evidence suggesting dizzy patients who avoid
head movements may be prone to motion sensitivity,
which can delay recovery and contribute to long-lasting
subjective dizziness and imbalance [31, 32]. A brief fur-
ther session, repeating the advice will be provided prior
to participant’s discharge. Following the last treatment
session, a repeat diagnostic test will be performed to as-
certain the presence of BPPV.
Intervention fidelity
Fidelity monitoring is an important part of any rehabili-
tation research intervention, enabling investigators to
differentiate between comparator and experimental in-
terventions and ensuring any procedures are carried
out as defined in the protocol or guidelines [33]. In this
study, video will be used to record therapists perform-
ing the interventions. Independent raters will observe
and evaluate approximately 10% of therapy sessions,
using a competency record sheet. This approach has
been previously utilised in studies evaluating treatment
fidelity [33].
Outcome measures
Baseline demographic data will be recorded including
age, gender, factors relating to the head injury, func-
tional status, falls and past medical history. Primary out-
come measures relate to feasibility objectives: number of
eligible patients, time taken to fulfil recruitment target,
trial dropout rates, variability in intervention fidelity,
proportion of outcome measures completed and any ad-
verse events noted throughout the trial.
Secondary outcomes will be collected at three
timepoints:
– Timepoint 0—during hospital stay, following
consent, randomisation and prior to treatment
– Timepoint 1—at 4 weeks following treatment
– Timepoint 2—at 12 weeks following treatment
Secondary outcomes comprise the diagnostic test for
BPPV (Dix Hallpike manoeuvre) to explore the fre-
quency and recurrence rate of BPPV, in addition to a
range of self-reported measures explored below.
Self-reported disability pertaining to dizziness will be
evaluated using the Dizziness Handicap Inventory
(DHI), a 25-item questionnaire with high test re-test re-
liability and low error of measurement score [34]. Dizzi-
ness frequency and severity will be examined by the
UCLA Dizziness questionnaire [35]. The Activities-
specific Balance Confidence scale will explore subjective
balance confidence by asking participants to rate how
balanced they feel completing sixteen different day to
Fig. 4 Simplified study flow chart
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day tasks. Previous research in older adults has demon-
strated scores less than 67% indicate a high risk of falling
[36].
Cognitive function will be screened using the Montreal
Cognitive Assessment (MoCA), a standardised test of
visuo-spatial and executive function, naming, memory,
attention, language, abstraction and orientation, rou-
tinely used in clinical settings [37]. Health outcome will
be measured using the EQ-5D, a widely used tool con-
sisting of five items regarding mobility, usual care activ-
ities, self-care, anxiety and depression and pain. Scores
will also be used for economic evaluation during a de-
finitive trial [38]. Anxiety and depression will be
screened using the Hospital Anxiety and Depression
scale (HADS). Participants respond by rating each ques-
tion on a 4-point scale, with higher scores indicating in-
creased levels of anxiety and/or depression [39].
Three further questionnaires will be used at timepoints
1 and 2 to explore functional recovery, return to work and
quality of life. The Glasgow Coma Outcome Score is a
tool extensively used in phase III trials as a primary meas-
ure of recovery following TBI [40]. The extended version
of the measure, via structured interview, splits the latter
three of five categories (death, vegetative state, severe dis-
ability, moderate disability and good recovery) into upper
and lower domains to improve sensitivity. Return to work
following TBI will be measured using the Work Quality
Index—a measure of both work status and stability [41].
Participants are divided into four working status categor-
ies, and then subsequently into four working stability do-
mains, giving a composite measure of work quality. The
Quality of Life after Brain Injury measure was specifically
developed for the TBI population and has been validated
through two large multi-centre studies [42]. Participants
rate their quality of life on 37 items in six scales assessing
areas of cognition, self, daily life and autonomy, social re-
lationships and their emotions and physical problems.
Objective balance outcomes (modified clinical test of
sensory integration in balance (mCTSIB) and modified
Dynamic Gait Index (mDGI)) will be measured at all three
time points. The mCTSIB evaluates how participants are
able to use sensory inputs during static balance in four
conditions; feet together and eyes open or closed on a
hard or soft surface for 30 s. This test has demonstrated
excellent reliability and validity in those with vestibular
disorders [43]. The mDGI comprises eight dynamic walk-
ing tasks. Raters evaluate gait pattern, level of assistance
and time taken to complete the task. The psychometric
properties of this measure have been investigated in sev-
eral neurological populations including TBI [44, 45].
Sample size
As this is a feasibility study, no formal sample size calcu-
lation has been undertaken. However, Sim and Lewis
[46] recommend at least 50 participants for this type of
study. Accordingly, approximately 25 participants will be
recruited into each arm, giving a total sample size of 75
patients. Our sample size compares favourably to previ-
ous trials investigating treatment of idiopathic BPPV [47,
48] and other feasibility studies [49, 50]. We will use sec-
ondary outcome measures to inform a sample size calcu-
lation for a future RCT.
A sample of up to ten patients who declined to take
part in the study will be interviewed to examine their
reasons for declining and therefore optimise recruitment
strategies for a future study. Approximately ten thera-
pists and 18 patients participating in the trial will also be
interviewed at the end of the trial to explore intervention
acceptability. Sample sizes for the qualitative component
were drawn up following consultation of relevant guid-
ance [51] which advocates an emphasis on sampling di-
versity as well as size in feasibility studies.
Phase 2—interviews with participants and therapists
The aim of this phase will be to explore the feasibility of
the trial from a participant and therapist perspective
using face to face, individual interviews. A topic guide
will be used to structure the interviews and will examine
participants’ and therapists’ views on the study design
and their experience of recruitment processes, assess-
ments, outcome measures, the intervention itself and
follow-up assessments. Data from this phase will be uti-
lised to refine the study procedures to maximise recruit-
ment for a subsequent RCT.
Potential participant interviewees will be purposively
sampled at the 12-week follow-up timepoint. A sample
of approximately 18 participants (6 from each treatment
arm across all centres) will explore the thoughts and
views of those taking part in the trial. Additionally, up to
10 participants who declined to participate in the study
will be invited to take part in individual interviews to ex-
plore reasons for non-participation. They will be inter-
viewed face to face or by telephone, according to
preference. Up to ten therapists participating in the trial
across all centres will be asked to consent to individual
interviews.
Planned data analysis
Results will be reported descriptively to chart demo-
graphic and observational data. Participant recruitment/
retention data will be reported using pilot and feasibility
CONSORT guidelines [52]. An estimate of the preva-
lence of BPPV in acute TBI will be reported with 95%
confidence intervals. The analysis will be undertaken on
an ‘intention to treat’ basis, i.e. analysis will include all
patients at the end of the study, whether or not they
complete the intervention. We will assess the predictors
of (i) return to work and (ii) BPPV at 3 months via a
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binary multiple logistic regression with predictors: DHI
score, intervention group, duration of post traumatic
amnesia and the presence of skull fracture. Our pro-
jected sample size of 75 patients should be sufficient to
test these regression models given that each one has four
variables. As there are two regression models, which
both use the same predictor variables, the alpha will be
adjusted (α = .025) based on the Bonferroni correction.
We do not expect to demonstrate significant results
from this data; rather, it will be used to calculate effect
sizes for future prospective treatment studies.
Qualitative data will be transcribed verbatim and ana-
lysed using a Framework approach [53, 54]. This type of
analysis uses a series of interconnected stages which en-
ables the researcher to move back and forth across the
data until a coherent account emerges. Following famil-
iarisation with the transcripts, a framework is developed
according to key issues or themes, into which data is
then indexed. Data is then summarised by category and
charted using the final coding index. Finally, key charac-
teristics and differences between data are identified,
allowing the generation of concepts, connections and
relationships.
Study monitoring and data protection
A steering group comprising of an external chair, statis-
tician, lay members and ward therapists from all sites
discussed and provided input into the protocol at the
planning stage. The steering group will meet throughout
the duration of the trial to monitor recruitment and any
adverse events. Additionally, a data monitoring commit-
tee will have access to unblinded data and will therefore
be able to oversee the safety of the trial participants.
Trial cessation criteria include any patient safety con-
cerns, the futility of treatment in a specific intervention
arm and recruitment of 75 patients.
Written data will be stored securely at individual NHS
centres. Study data will be collected and managed using
REDcap electronic data capture tools hosted at Imperial
College London [55, 56]. REDcap (Research Electronic
Data Capture) is a secure, web-based software platform
designed to support data capture for research studies.
Trial progression criteria
Trial progression criteria will be used to determine
whether it is appropriate to move forwards to a RCT.
Criteria include:
– 60% of those screened eligible for inclusion.
– Initially 30% of eligible patients are expected to
consent to participate in the study, rising to 50% of
those eligible consented as the research team gain
confidence with consenting procedures.
– ≤ 40% drop out rate.
Thresholds for participants consenting have been in-
formed from previous feasibility studies in acute TBI
[57, 58] and reflect some of the challenges of recruiting
acute TBI patients [59].
Patient and public involvement
This feasibility trial was designed following discussions
with patients from a specific brain injury charity. Patient
members form an important component of the steering
group. Feedback from patient members was invited on
the proposed trial design, protocol and participant facing
documents, such as information sheets and topic guides
for interviews. Patients and the public will play a central
role in planning dissemination of results and future
steps.
Discussion
This paper describes the rationale and the methods of a
mixed methods feasibility trial for managing BPPV in
acute TBI. The results of this feasibility trial will not
only inform the design and development of a future
RCT, but will also highlight and describe the prevalence
of BPPV in this population. Long-term implications of
diagnosing and treating BPPV early on in acute TBI may
have a positive impact on patient centric outcomes in-
cluding reduced symptom load, attenuated falls risk and
a shortened delay in return to work. Additional service
benefits include a reduced hospital length of stay, im-
proved rehabilitation outcome and a lessened burden on
outpatient resources following discharge.
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